Todos os estudos
Inscrição por conviteFASE3INTERVENCIONISTA

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

This study, called ADVANCE EXTENSION, is designed for people with a specific type of lung condition called WHO Group 1 Pulmonary Arterial Hypertension (PAH). Participants must have already taken part in an earlier study looking at the drug Ralinepag. The main goal is to understand how well Ralinepag works and if it's safe over a longer period. Participants will continue to receive Ralinepag alongside any other PAH medications they are already taking. It's an "open-label" study, meaning everyone involved, including the participants and doctors, will know they are receiving Ralinepag. This research helps us learn more about the long-term use of this medication for PAH.

Em resumo

Sobre o que é este estudo?

This study, known as ADVANCE EXTENSION, is a continuation for people who have already been involved in a study testing a drug called Ralinepag for a serious lung condition called Pulmonary Arterial Hypertension (PAH). PAH is a rare disease where the blood vessels in the lungs become narrow, making it difficult for the heart to pump blood through them. This can lead to symptoms like breathlessness and tiredness.

The main purpose of this study is to gather more information about the long-term effects of Ralinepag. Specifically, doctors want to see how well the drug continues to work over time to help manage PAH, and to track any side effects that might occur with long-term use. The study is "open-label," which means that everyone involved – the participants, the doctors, and the researchers – will know that Ralinepag is being given. This is different from a "blinded" study where some people might receive a placebo (a dummy pill).

If you join this study, you will continue to receive Ralinepag. This will be in addition to any other medicines you are already taking for your PAH. The information collected from this study is really important because it helps medical professionals understand how to best use Ralinepag to help people live better with PAH in the long run. The study will continue until the drug is approved and available more widely, or if the study needs to end for other reasons.

Pontos principais

  • This study is for people with PAH who have previously taken Ralinepag.
  • Its main aim is to understand the long-term safety and effectiveness of Ralinepag.
  • Participants will know they are receiving Ralinepag (it's 'open-label').
  • Ralinepag will be given alongside your usual PAH medications.
  • Regular check-ups and tests will monitor your health and the drug's effects.
  • Você pode deixar o estudo a qualquer momento sem afetar seu atendimento normal.

Quem pode ser elegível?

To be considered for this study, you must have already taken part in a previous study involving the drug Ralinepag for your Pulmonary Arterial Hypertension (PAH). You also need to have successfully completed all the required steps of that earlier study.

It's important that you are willing and able to attend all scheduled appointments, follow the treatment plan, and have necessary tests done. If you are a man or woman who could become pregnant, you'll need to agree to use effective contraception throughout the study and for 30 days after taking your last dose of Ralinepag. This also means not trying to become pregnant or making someone pregnant during this time.

Unfortunately, you won't be able to join if you had to stop your previous Ralinepag study because of serious side effects or if you didn't finish all the necessary procedures in that study. You also cannot participate if you decided to stop your involvement in a previous Ralinepag study, are pregnant or breastfeeding, or have recently had a lung or heart/lung transplant since your last Ralinepag study.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I have previously participated in a study involving Ralinepag for PAH.
  2. I completed all the required steps of that previous Ralinepag study.
  3. I am aged 18 years or older.
  4. I am willing to attend all study visits and undergo tests.
  5. If I can become pregnant or make someone pregnant, I agree to use contraception during the study.
  6. I have not had a lung or heart/lung transplant since my last Ralinepag study.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you will receive the drug Ralinepag. You will continue to take Ralinepag along with any other medications you are already using for your PAH. If you're coming from a study where you didn't know if you were getting Ralinepag or a placebo, you might have a 16-week period where the dose is adjusted, but you'll still be receiving Ralinepag.

Throughout the study, you'll have regular hospital or clinic visits where you'll be checked by the doctors and nurses. These visits will involve various tests to monitor your health and how you're responding to the medication, such as blood tests or heart and lung assessments. The doctors will also keep track of any side effects you experience.

There's no set total duration for this extension study. You will continue to receive Ralinepag for as long as the study is ongoing, unless you or your doctor decide it's best for you to stop, or if Ralinepag becomes widely available in your area.

Riscos e benefícios potenciais

The potential benefits of taking part include continued access to Ralinepag, which may help manage your PAH, and contributing to important medical research that could help others with PAH in the future. As with any drug, Ralinepag may have side effects, and some could be serious. The research team will carefully monitor you for any problems. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (190)

  • St. Joseph's Hospital and Medical Center-Norton Thoracic Institute
    Código postal verificado
    Phoenix, Estados Unidos
  • Universidade do Arizona
    Código postal verificado
    Tucson, Estados Unidos
  • UCSD Health Sciences
    Código postal verificado
    La Jolla, Estados Unidos
  • Ronald Reagan UCLA Medical Center
    Código postal verificado
    Los Angeles, Estados Unidos
  • Keck Hospital of USC
    Código postal verificado
    Los Angeles, Estados Unidos
  • VA Greater Los Angeles Healthcare System
    Código postal verificado
    Los Angeles, Estados Unidos
  • University of California, Irvine
    Código postal verificado
    Orange, Estados Unidos
  • Centro Médico da Universidade da Califórnia em Davis
    Código postal verificado
    Sacramento, Estados Unidos
  • Santa Barbara Cottage Hospital
    Código postal verificado
    Santa Barbara, Estados Unidos
  • Stanford University Medical Center
    Código postal verificado
    Stanford, Estados Unidos
  • University of Colorado Hospital
    Código postal verificado
    Aurora, Estados Unidos
  • Saúde Judaica Nacional
    Código postal verificado
    Denver, Estados Unidos

Perguntas frequentes

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a serious condition where the blood vessels in your lungs become narrowed, making it harder for your heart to pump blood through them. This can cause symptoms like breathlessness and fatigue.

What is an 'open-label' study?

In an open-label study, both you and your doctor will know that you are receiving the study drug (Ralinepag). This is different from a 'blinded' study where you might not know if you're getting the drug or a dummy pill.

Will I take Ralinepag instead of my current PAH medicines?

No, you will continue to take Ralinepag in addition to your existing PAH medications. It's meant to work alongside what you're already taking.

What happens if Ralinepag becomes available outside the study?

If Ralinepag gets approved and becomes widely available where you live, the study may end for you, and your doctor can then prescribe it to you if appropriate.

Posso parar de participar do estudo a qualquer momento?

Yes, you are free to withdraw from the study at any point and for any reason, without it affecting your ongoing medical care.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study Evaluating the Long-Term Efficacy and Safety of Rali…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.